鲁股观察 | 信得科技冲刺港交所

Core Viewpoint - Shandong Xinde Technology Co., Ltd., a "hidden champion" in the pet economy, has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, indicating its ambition to expand in the capital market [1]. Company Overview - Xinde Technology ranks ninth among domestic manufacturers in China's animal health market with a market share of approximately 1.4% as of 2024 [3]. - The company is a leader in the poultry veterinary biological products market, holding the top position in specific categories such as veterinary transfer factors, Newcastle disease vaccines, and avian mycoplasma vaccines [4]. - Xinde Technology has developed 12 national-level new veterinary drugs and is one of the first companies globally to use suspension culture technology for producing highly pathogenic avian influenza vaccines [4]. Business Model - The company’s business model focuses on providing "precise prevention and control solutions" through "precise flow regulation, precise customization, and precise evaluation," along with high-cost performance products via innovation and large-scale production [4]. - Approximately 70% of the company's revenue in the first nine months of 2025 came from direct sales to end farming customers, reflecting a strong relationship with large poultry and livestock farms [4]. Financial Performance - Financial data shows that Xinde Technology's revenue for 2023, 2024, and the first nine months of 2025 was RMB 985 million, RMB 982 million, and RMB 877 million, respectively [7]. - The company's profit figures were RMB 34.76 million, RMB 28.12 million, and RMB 55.67 million for the same periods, indicating significant profit volatility with a 19% decline in 2024 but a 117.6% increase in the first nine months of 2025 [7]. - The gross profit margin remained high, fluctuating between 46% and 49.7%, primarily due to the focus on veterinary biological products [7]. Shareholding Structure - The founder and chairman, Li Chaoyang, controls 45.08% of the voting rights, while SANY Hong Kong Group holds approximately 2.98% [7]. - The presence of state-owned and professional investment institutions in the shareholder structure indicates diverse capital recognition [7]. IPO and Future Plans - The funds raised from the IPO will be primarily used for capacity expansion, production line upgrades, R&D in new vaccines and pet medications, and expanding domestic and international sales networks [8]. - Despite rapid growth in overseas revenue from RMB 12.2 million in 2023 to RMB 46.1 million in the first nine months of 2025, the domestic market still accounts for 94.7% of total revenue, indicating a need for further validation of expansion efforts [8].